DALLAS, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Dougherty’s Pharmacy, Inc. (the “Company”) (OTCQB:MYDP) is pleased to announce that it has been approved to upgrade its common stock from the Pink® Open Market to the OTCQB® Venture Market, effective today, August 29, 2017.

“We are pleased to announce the Company’s upgrade to the OTCQB® Venture Market.  We believe this upgrade will assist our current and future shareholders by providing an improved trading market for our Company’s stock and enhance shareholder value,” said President and CFO, Mark Heil. 

About Dougherty’s Pharmacy, Inc.

Dougherty’s Pharmacy, Inc. is a retail pharmacy chain focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region of the United States. On June 9, 2017, the Company changed its name from Ascendant Solutions, Inc. to Dougherty’s Pharmacy, Inc. to better reflect the corporate vision and operating structure. Dougherty’s currently has approximately $48 million in net operating loss carryforwards which can be used to shelter future income, thus enhancing free cash flow or debt service capabilities. Interested investors can access financials and stock trading information for Dougherty’s at OTCMarkets.com or at www.doughertys.com.  

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Securities Act of 1933, the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's current expectations, projections, estimates and assumptions. These forward-looking statements may be identified by words such as "expects," "believes," "anticipates" and similar expressions.  Forward-looking statements involve risks and uncertainties that may cause future results to differ materially from those suggested by the forward-looking statements.  The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances. 

Contacts:	

Mark S. Heil
President and CFO
972-250-0945

Geralyn DeBusk or Tom Carey
Halliburton Investor Relations
972-458-8000